Multiple Sclerosis

BMI Not Found to Affect Cognitive Function, Brain Volume in Patients With RRMS

November 24th 2021, 5:08pm


Body mass index (BMI) was not identified as a factor influencing cognitive function or brain mass in patients with relapsing-remitting multiple sclerosis (RRMS), investigators of a recent analysis concluded.

Specific Growth Factor Found to Increase Risk of MS

November 23rd 2021, 2:30pm


In a study assessing the impacts of 5 growth factors on MS, fibroblast growth factor 23 was identified to increase the risk of patients experiencing the onset and progression of multiple sclerosis (MS).

European Commission Approves Biogen’s Vumerity as Oral RRMS Therapy

November 18th 2021, 8:30pm


The European Commission gave its stamp of approval for Vumerity (diroximel fumarate), developed by Biogen, as an oral treatment for patients with relapsing-remitting multiple sclerosis (RRMS).

Anti-CD20 Therapies May Increase Risk of Severe COVID-19 in Patients With MS

November 17th 2021, 3:30pm


Anti-CD20 disease-modifying therapies, including rituximab and ocrelizumab, were found to increase the risk of hospitalization and intensive care unit admission in patients with multiple sclerosis (MS) who develop COVID-19, investigators concluded in this new study.

Study Identifies Factors Influencing the Degree of Disability in MS

November 10th 2021, 9:35pm


Drug use, serum albumin, and total number of lesions may serve as independent factors influencing the degree of disability in patients with multiple sclerosis (MS), investigators of a retrospective analysis concluded.

Atypical Radiological, Lab Findings Linked to Choice of Therapy in Patients With MS

November 7th 2021, 6:45pm


Choice of therapy to manage multiple sclerosis (MS) and prevent relapse was found to influence radiological and laboratory results, including lesion presentation, giving insight into the paraclinical characteristics of patients receiving different MS therapies.

Patients With MS Have Similar Risks for COVID-19 Complications vs Other Populations

November 3rd 2021, 1:34pm


Patients with multiple sclerosis (MS) had similar factors associated with adverse COVID-19 outcomes vs other populations, but these risks were found to decrease with subsequent COVID-19 waves, investigators found.

Study: Video Game Therapy Has Minimal Effect on Postural Balance in Patients With MS

November 1st 2021, 8:15pm


Video game therapy was found to have a minor impact on postural balance in patients with multiple sclerosis (MS); however, more research is needed to determine whether it should be recommended in clinical practice, investigators concluded.

Patients With MS Testing Positive for COVID-19 Saw Worse Depressive, Anxiety Symptoms

October 29th 2021, 10:33pm


A recent study found patients with multiple sclerosis (MS) experienced depressive and anxiety symptoms during the COVID-19 pandemic prior to vaccine rollout, especially among those who tested positive for COVID-19.

Study: Online Resources Don’t Match Established Physical Activity, Exercise Training Guidelines for MS

October 19th 2021, 5:00pm


A study confirmed that many online resources showed inconsistencies or omissions compared with established guidelines related to physical activity and exercise training, which are known to provide clinical benefits for patients with multiple sclerosis (MS).